Cited by 1,149Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolismTrace Elements in Health

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., Marsden, C. D.·1989·Journal of Neurochemistry

DOI 10.1111/j.1471-4159.1989.tb07264.x

Open this paper in CoChat — free account

Abstract

Levels of iron, copper, zinc, manganese, and lead were measured by inductively coupled plasma spectroscopy in parkinsonian and age-matched control brain tissue. There was 31-35% increase in the total iron content of the parkinsonian substantia nigra when compared to control tissue. In contrast, in the globus pallidus total iron levels were decreased by 29% in Parkinson's disease. There was no change in the total iron levels in any other region of the parkinsonian brain. Total copper levels were reduced by 34-45% in the substantia nigra in Parkinson's disease; no difference was found in the other brain areas examined. Zinc levels were increased in substantia nigra in Parkinson's disease by 50-54%, and the zinc content of the caudate nucleus and lateral putamen was also raised by 18-35%. Levels of manganese and lead were unchanged in all areas of the parkinsonian brain studied when compared to control brains, except for a small decrease (20%) in manganese content of the medial putamen. Increased levels of total iron in the substantia nigra may cause the excessive formation of toxic oxygen radicals, leading to dopamine cell death.

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.1989.tb07264.x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Self-citation
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,377
FERRITIN: STRUCTURE, GENE REGULATION, AND CELLULAR FUNCTION IN ANIMALS, PLANTS, AND MICROORGANISMS
Theil, E. C. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.001445 · Cited by 1,337
Increased nigral iron content in postmortem parkinsonian brain
Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963
Self-citation
Autoxidation versus Covalent Binding of Quinones as the Mechanism of Toxicity of Dopamine, 6-Hydroxydopamine, and Related Compounds toward C1300 Neuroblastoma Cells in Vitro
Graham, D. G., Tiffany, S. M., BELL, W. R., & Gutknecht, W. F. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13536-0 · Cited by 953
The importance of free radicals and catalytic metal ions in human diseases.
Halliwell, B., & Gutteridge, J. M. C. (1985) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(85)90001-9 · Cited by 941
Iron-Responsive Elements: Regulatory RNA Sequences That Control mRNA Levels and Translation
Casey, J. L., Hentze, M. W., Koeller, D. M., Caughman, S. W., Rouault, T. A., Klausner, R. D., & Harford, J. B. (1988) · Science · doi:10.1126/science.2452485 · Cited by 709
Brain Peroxidase and Catalase in Parkinson Disease
Ambani, L. M., Woert, M. H. V., & Murphy, S. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490440064010 · Cited by 404

Show all 29 references

Research works printed but not linked: 4

Barbeau A., 1985, Uneven prevalence of Parkinson's disease in the province of Quebec, Can. J. Neurol. Sci., 12, 169
Barbeau A., 1986, Advances in Neurology, 299
Donaldson J., 1974, Advances in Neurology, 245
Youdim M. B. H., 1985, Handbook of Neurochemisiry, 731

Sorted by citations

Items 101–200 of 1,000

Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat
Burdo, J. R., Menzies, S. L., Simpson, I. A., Garrick, L. M., Garrick, M. D., Dolan, K. G., Haile, D. J., Beard, J. L., & Connor, J. R. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1256 · Cited by 297
Glutathione‐related enzymes in brain in Parkinson's disease
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S. E., Jenner, P. G., & MARSDEN, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360306 · Cited by 296
Self-citation
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 296
Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia
Dexter, D. T., Jenner, P. G., Schapira, A. H. V., & MARSDEN, C. D. (1992) · Annals of Neurology · doi:10.1002/ana.410320716 · Cited by 292
Self-citation
Brain iron uptake and homeostatic mechanisms: An overview
Burdo, J. R., & Connor, J. R. (2003) · BioMetals · doi:10.1023/a:1020718718550 · Cited by 295
Oxygen free radicals and Parkinson's disease
Adams, J. D., Jr., & Odunze, I. N. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90009-r · Cited by 289
Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition
Siddiq, A., Ayoub, I. A., Chavez, J. C., Aminova, L. R., Shah, S., LaManna, J. C., Patton, S. M., Connor, J. R., Cherny, R. A., Volitakis, I., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504963200 · Cited by 282
Alpha-synuclein and Parkinson's disease
Lücking, C. B., & Brice, A. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000671 · Cited by 289
The Effects of Methamphetamine on the Production of Free Radicals and Oxidative Stress
Yamamoto, B. K., & Zhu, W. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37769-9 · Cited by 281
The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer’s and Parkinson’s diseases1,2 11Guest Editors: Mark A. Smith and George Perry 22This article is part of a series of reviews on “Causes and Consequences of Oxidative Stress in Alzheimer’s Disease.” The full list of papers may be found on the homepage of the journal.
Giasson, B. I., Ischiropoulos, H., Lee, V. M. ‐., & Trojanowski, J. Q. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00804-3 · Cited by 285
Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care
Wang, Y., Spincemaille, P., Liu, Z., Dimov, A., Deh, K., Li, J., Zhang, Y., Yao, Y., Gillen, K. M., Wilman, A. H., et al. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25693 · Cited by 285
Oxytosis/Ferroptosis—(Re-) Emerging Roles for Oxidative Stress-Dependent Non-apoptotic Cell Death in Diseases of the Central Nervous System
Lewerenz, J., Ates, G., Methner, A., Conrad, M., & Maher, P. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00214 · Cited by 276
Oxygen Free Radicals and Brain Dysfunction
Jesberger, J. A., & Richardson, J. S. (1991) · International Journal of Neuroscience · doi:10.3109/00207459109150342 · Cited by 273
Dopamine, Oxidative Stress and Protein–Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases
Monzani, E., Nicolis, S., Dell’Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 274
Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
Fão, L., Mota, S. I., & Rego, A. C. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100942 · Cited by 281
Diffusion anisotropy MRI for quantitative assessment of recovery in injured rat spinal cord
Nevo, U., Hauben, E., Yoles, E., Agranov, E., AKSELROD, S., Schwartz, M., & Neeman, M. (2001) · Magnetic Resonance in Medicine · doi:10.1002/1522-2594(200101)45:1 · Cited by 137
Sequestration of iron by Lewy bodies in Parkinson's disease
Castellani, R. J., Siedlak, S. L., Perry, G., & Smith, M. A. (2000) · Acta Neuropathologica · doi:10.1007/s004010050001 · Cited by 265
Tyrosine Hydroxylase and Parkinson’s Disease
Haavik, J., & Toska, K. (1998) · Molecular Neurobiology · doi:10.1007/bf02741387 · Cited by 263
Decreased ferritin levels in brain in Parkinson's disease
Dexter, D. T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., Lees, A. J., Wells, F. R., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb08814.x · Cited by 258
Self-citation
NRF2, a Superstar of Ferroptosis
Yan, R., Lin, B., Jin, W., Tang, L., Hu, S., & Cai, R. (2023) · Antioxidants · doi:10.3390/antiox12091739 · Cited by 292
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases
Chen, L., Shen, Q., Liu, Y., Zhang, Y., Sun, L., Ma, X., Song, N., & Xie, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02071-0 · Cited by 279
The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases
Dušek, P., Roos, P. M., Litwin, T., Schneider, S. A., Flaten, T. P., & Aaseth, J. (2014) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2014.05.007 · Cited by 260
Dietary Antioxidants and Parkinson Disease
de Rijk, M. C. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550180070015 · Cited by 250
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats
Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.005 · Cited by 246
The transition metals copper and iron in neurodegenerative diseases
Rivera-Mancía, S., Pérez‐Neri, I., Ríos, C., Tristán-López, L. A., Rivera-Espinosa, L., & Montes, S. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.04.010 · Cited by 247
Copper pathology in vulnerable brain regions in Parkinson's disease
Davies, K. M., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D. J., Finberg, J. P. M., Reyes, S., Halliday, G. M., Mercer, J. F. B., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.034 · Cited by 244
Neuromelanin of the Human Substantia Nigra: An Update
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243
Environmental Factors in Parkinson’s Disease
Monte, D. A. D., Lavasani, M., & Manning-Bog, A. (2002) · NeuroToxicology · doi:10.1016/s0161-813x(02)00099-2 · Cited by 244
Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders
Loeffler, D. A., LeWitt, P. A., Juneau, P. L., Sima, A. A. F., Nguyen, H.-U., DeMaggio, A. J., Brickman, C. M., Brewer, G. J., Dick, R. D., Troyer, M. D., et al. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00782-2 · Cited by 237
Iron and neurodegenerative disorders
Thompson, K. J., Shoham, S., & Connor, J. R. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00510-x · Cited by 235
The Metabolism of Neuronal Iron and Its Pathogenic Role in Neurological Disease: Review
Moos, T., & Morgan, E. H. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.002 · Cited by 234
Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28
YOUDIM, M. B. H., STEPHENSON, G., & SHACHAR, D. B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.025 · Cited by 233
Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease
Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F. A., Engelen, M., Żądło, A. C., Szewczyk, G. M., Zaręba, M., & Sarna, T. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05541.x · Cited by 233
Single Particle Characterization of Iron-induced Pore-forming α-Synuclein Oligomers
Kostka, M., Högen, T., Danzer, K. M., Levin, J., Habeck, M., Wirth, A., Wagner, R., Glabe, C. G., Finger, S., Heinzelmann, U., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709634200 · Cited by 233
Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease
Faucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229
Self-citation
Iron in the basal ganglia in Parkinson's disease
Griffiths, P. D., Dobson, B. R., Jones, G. R., & Clarke, D. T. (1999) · Brain · doi:10.1093/brain/122.4.667 · Cited by 229
Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes
Walter, U., Niehaus, L., Probst, T., Benecke, R., Meyer, B.-U., & Dressler, D. W. (2003) · Neurology · doi:10.1212/wnl.60.1.74 · Cited by 229
Copper Ions and Parkinson’s Disease: Why Is Homeostasis So Relevant?
Bisaglia, M., & Bubacco, L. (2020) · Biomolecules · doi:10.3390/biom10020195 · Cited by 226
Oxygen Radicals and Neuropsychiatric Illness
Lohr, J. B. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360061009 · Cited by 225
Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease
Datla, K. P., Christidou, M., Widmer, W. W., ROOPRAI, H. K., & Dexter, D. T. (2001) · Neuroreport · doi:10.1097/00001756-200112040-00053 · Cited by 224
Self-citation
Contributory mechanisms in the causation of neurodegenerative disorders
Lees, G. J. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90254-d · Cited by 223
Lazaroids improve the survival of grafted rat embryonic dopamine neurons.
Nakao, N., Grasbon-Frodl, E. M., Duan, W. M., Widner, H., & Brundin, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12408 · Cited by 220
Neuronal Apoptosis in Neurodegeneration
Okouchi, M., Ekshyyan, O. Y., Maracine, M., & Aw, T. Y. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1511 · Cited by 222
(E)-4-Hydroxy-2-Nonenal May be Involved in the Pathogenesis of Parkinson’s Disease
Selley, M. L. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00021-5 · Cited by 215
In vivo detection of iron and Neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage
Zecca, L., Berg, D., Arzberger, T., Ruprecht, P., Rausch, W. D., Musicco, M., Tampellini, D., Riederer, P., Gerlach, M., & Becker, G. (2005) · Movement Disorders · doi:10.1002/mds.20550 · Cited by 214
Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist
Iida, M., Miyazaki, I., Tanaka, K.-I., Kabuto, H., Iwata‐Ichikawa, E., & Ogawa, N. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01688-1 · Cited by 211
Meta-analysis of brain iron levels of Parkinson’s disease patients determined by postmortem and MRI measurements
Wang, J., Zhuang, Q.-Q., Zhu, L.-B., Zhu, H., Li, T., Li, R., Chen, S., Huang, C.-P., Zhang, X., & Zhu, J. (2016) · Scientific Reports · doi:10.1038/srep36669 · Cited by 210
Brain Iron Homeostasis: From Molecular Mechanisms To Clinical Significance and Therapeutic Opportunities
Singh, N., Haldar, S., Tripathi, A. K., Horback, K., Wong, J., Sharma, D., Beserra, A., Suda, S., Anbalagan, C., Dev, S., et al. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4931 · Cited by 208
Metals ions and neurodegeneration
Molina‐Holgado, F., Hider, R. C., Gaeta, A., Williams, R., & Francis, P. T. (2007) · BioMetals · doi:10.1007/s10534-006-9033-z · Cited by 206
Medicinal Profile, Phytochemistry, and Pharmacological Activities of Murraya koenigii and its Primary Bioactive Compounds
Balakrishnan, R., Vijayraja, D., Jo, Ganesan, P., Su-Kim, I., & Choi, D. (2020) · Antioxidants · doi:10.3390/antiox9020101 · Cited by 207
Oxidative stress as a cause of Parkinson's disease
Jenner, P. G., & Jenner, P. G. (1991) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1991.tb05013.x · Cited by 205
Self-citation
Oxidative and nitrative protein modifications in Parkinson's disease
Danielson, S. R., & Andersen, J. K. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.005 · Cited by 204
Copper and Copper Proteins in Parkinson’s Disease
Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L., & Rios, C. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/147251 · Cited by 203
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.
Zecca, L., Tampellini, D., Gerlach, M., Riederer, P. F., Fariello, R. G., & Sulzer, D. L. (2001) · Europe PMC (PubMed Central) · doi:10.1136/mp.54.6.414 · Cited by 200
Dopamine- and l-β-3,4-dihydroxyphenylalanine hydrochloriDe (l-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y Cells
Lai, C., & Yu, P. H. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00731-9 · Cited by 198
Basic FGF, NGF, and IGFs Protect Hippocampal and Cortical Neurons against Iron-Induced Degeneration
Zhang, Y., Tatsuno, T., Carney, J. M., & Mattson, M. P. (1993) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1993.51 · Cited by 195
Interaction of neuromelanin and iron in substantia nigra and other areas of human brain
Zecca, L., Shima, T., Stroppolo, A., Goj, C., Battiston, G. A., Gerbasi, R., Sarna, T., & Swartz, H. M. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00047-4 · Cited by 197
Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats
Ben‐Shachar, D., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb06432.x · Cited by 197
Progress in Parkinson's disease—Where do we stand?
Toulouse, A., & Sullivan, A. M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.003 · Cited by 197
The biochemistry of aging
Knight, J. A. (2001) · Advances in clinical chemistry · doi:10.1016/s0065-2423(01)35014-x · Cited by 197
Delineation of an endogenous zinc‐binding site in the human dopamine transporter
Nørregaard, L., Frederiksen, D., Nielsen, E. Ø., & Gether, U. (1998) · The EMBO Journal · doi:10.1093/emboj/17.15.4266 · Cited by 195
Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease
Franco-Iborra, S., Vila, M., & Perier, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00342 · Cited by 197
Neuronal vulnerability in Parkinson’s disease
Hirsch, É. C., Faucheux, B. A., Damier, P., Prigent, A., & Agid, Y. (1997) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6842-4_9 · Cited by 192
Self-citation
Targets for neuroprotection in Parkinson's disease
Yacoubian, T. A., & Standaert, D. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.009 · Cited by 193
Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice
Callier, S., Morissette, M., Grandbois, M., Pélaprat, D., & Paolo, T. D. (2001) · Synapse · doi:10.1002/syn.1067 · Cited by 186
Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases.In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion
Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185
Metal ions as modulators of protein conformation and misfolding in neurodegeneration
Leal, S. S., Botelho, H. M., & Gomes, C. M. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.04.004 · Cited by 187
Brain Iron Metabolism Dysfunction in Parkinson’s Disease
Jiang, H. F., Wang, J., Rogers, J. T., & Xie, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9879-1 · Cited by 188
Iron-binding characteristics of neuromelanin of the human substantia nigra
Double, K. L., Gerlach, M., Schünemann, V., TRAUTWEIN, A. X., Zecca, L., Gallorini, M., Youdim, M. B. H., Riederer, P. F., & Ben‐Shachar, D. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00293-4 · Cited by 182
Increased Oxidative Damage and Decreased Antioxidant Function in Aging Human Substantia Nigra Compared to Striatum: Implications for Parkinson’s Disease
Venkateshappa, C., Harish, G., Mythri, R. B., Mahadevan, A., Bharath, M. M. S., & Shankar, S. K. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0619-7 · Cited by 177
MRI characteristics of the substantia nigra in Parkinson's disease: A combined quantitative T1 and DTI study
Menke, R., Scholz, J., Miller, K. L., Deoni, S., Jbabdi, S., Matthews, P. M., & Zarei, M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.05.017 · Cited by 176
A review of metal‐catalyzed molecular damage: protection by melatonin
Romero, A., Ramos, E., Rı́os, C. D. L., Egea, J., del Pino, J., & Reiter, R. J. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12132 · Cited by 176
α-synuclein aggregation and its modulation
Ghosh, D., Mehra, S., Sahay, S., Singh, P. K., & Maji, S. K. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.10.021 · Cited by 193
Glial Cells Protect Neurons Against Oxidative Stress via Transcriptional Up‐Regulation of the Glutathione Synthesis
Iwata‐Ichikawa, E., Kondo, Y., Miyazaki, I., Asanuma, M., & Ogawa, N. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722334.x · Cited by 173
Role of mitochondria in the etiology and pathogenesis of Parkinson's disease
Mizuno, Y., Ikebe, S., Hattori, N., Nakagawa-Hattori, Y., Mochizuki, H., Tanaka, M., & Ozawa, T. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00038-6 · Cited by 170
Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease
Palmer, A. M., & Burns, M. A. (1994) · Brain Research · doi:10.1016/0006-8993(94)91670-5 · Cited by 171
Quantitative susceptibility mapping of the midbrain in Parkinson's disease
Du, G., Liu, T., Lewis, M. M., Kong, L., Wang, Y., Connor, J. R., Mailman, R. B., & Huang, X. (2015) · Movement Disorders · doi:10.1002/mds.26417 · Cited by 167
Astroglia as Metal Depots: Molecular Mechanisms for Metal Accumulation, Storage and Release
Tiffany‐Castiglioni, E., & Qian, Y. (2001) · NeuroToxicology · doi:10.1016/s0161-813x(01)00050-x · Cited by 166
Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease
Carboni, E., & Lingor, P. (2015) · Metallomics · doi:10.1039/c4mt00339j · Cited by 170
Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration
Finazzi, D., & Arosio, P. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1329-0 · Cited by 166
Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse
Perfeito, R., Cunha‐Oliveira, T., & Rego, A. C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.042 · Cited by 169
Usefulness of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson Disease
Murakami, Y., Kakeda, S., Watanabe, K., Ueda, I., Ogasawara, A., Moriya, J., Ide, S., Futatsuya, K., Satô, T., Okada, K., et al. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4260 · Cited by 165
The Role of NADPH Oxidase 1–Derived Reactive Oxygen Species in Paraquat-Mediated Dopaminergic Cell Death
Cristóvão, A. C., Choi, D.-H., Baltazar, G., Beal, M. F., & Kim, Y.-S. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2459 · Cited by 167
Iron accumulation in the substantia nigra in rats visualized by ultrasound
Berg, D., Grote, C., Rausch, W., Mäurer, M., Wesemann, W., Riederer, P. F., & Becker, G. (1999) · Ultrasound in Medicine & Biology · doi:10.1016/s0301-5629(99)00046-0 · Cited by 165
Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease
Kampen, J. M. V., Robertson, H. A., Hagg, T., & Drobitch, R. K. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.08.002 · Cited by 164
Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases
Gu, M., Owen, A., Toffa, S., Cooper, J. A. D., Dexter, D. T., Jenner, P. G., MARSDEN, C. D., & Schapira, A. H. V. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00095-1 · Cited by 164
Self-citation
Protective effect of melatonin in a chronic experimental model of Parkinson’s disease
Antolı́n, I., Mayo, J. C., Sainz, R. M., del Brı́o, M. D. L. A., Herrera, F., Martı́n, V., & Rodrı́guez, C. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02551-9 · Cited by 166
Localization of copper and copper transporters in the human brain
Davies, K. M., Hare, D. J., Cottam, V., Chen, N., Hilgers, L., Halliday, G. M., Mercer, J. F. B., & Double, K. L. (2012) · Metallomics · doi:10.1039/c2mt20151h · Cited by 163
Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease
Jenner, P. G. (1993) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb00013.x · Cited by 163
Self-citation
Parkinson's disease mortality and the industrial use of heavy metals in Michigan
Rybicki, B. A., Johnson, C. C., Uman, J. E., & Gorell, J. M. (1993) · Movement Disorders · doi:10.1002/mds.870080116 · Cited by 163
Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain
Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., & Sabbioni, E. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031097.x · Cited by 163
Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease
Du, G., Lewis, M. M., Styner, M. A., Shaffer, M. L., Sen, S., Yang, Q. X., & Huang, X. (2011) · Movement Disorders · doi:10.1002/mds.23643 · Cited by 162
Free Radicals in Human Health and Disease
Yadav, U. C. S., & Rani, V. (2014) · Springer eBooks · doi:10.1007/978-81-322-2035-0 · Cited by 163
Nigral Iron Elevation Is an Invariable Feature of Parkinson’s Disease and Is a Sufficient Cause of Neurodegeneration
Ayton, S., & Lei, P. (2014) · BioMed Research International · doi:10.1155/2014/581256 · Cited by 163
Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro
Ogawa, N., Tanaka, K.-I., Asanuma, M., Kawai, M., Masumizu, T., Kohno, M., & Mori, A. (1994) · Brain Research · doi:10.1016/0006-8993(94)90969-5 · Cited by 160
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
Lan, J., & Jiang, D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01277665 · Cited by 160
Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism
Liu, X., Shibata, T., Hisaka, S., & Osawa, T. (2008) · Brain Research · doi:10.1016/j.brainres.2008.11.076 · Cited by 158
Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes
Wang, Y., Wu, S., Li, Q., Sun, H., & Wang, H. (2023) · Advanced Science · doi:10.1002/advs.202300325 · Cited by 171
Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study
Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90833-8 · Cited by 156

Authors: Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D.
Affiliations: King's College London (GB)
National Hospital for Neurology and Neurosurgery (GB)
Inserm (FR)
Corresponding author: Jenner, P.
ORCID: Dexter, D. T.
Jenner, P.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 1989-06
Volume: 52
Issue: 6
Pages: 1830-1836
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1111/j.1471-4159.1989.tb07264.x
OpenAlex: W1985613988
Cited by: 1,149
References: 29
Citations by year: 2026: 18 · 2025: 26 · 2024: 31 · 2023: 32 · 2022: 46 · 2021: 42 · 2020: 35 · 2019: 33 · 2018: 35 · 2017: 41 · 2016: 45 · 2015: 21 · 2014: 37 · 2013: 45 · 2012: 41
FWCI: 24.67
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 6335 d)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
Keywords: Parkinson's disease, substantia nigra, iron, copper, zinc, manganese, lead, globus pallidus, caudate nucleus, putamen, oxidative stress, neurodegeneration
MeSH terms: Aged, Aged, 80 and over, Brain, Female, Humans, Ions, Iron, Male, Metals, Parkinson Disease, Substantia Nigra, Tissue Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks